Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from SNY

Kevin Durant wants trade to Celtics; 76ers interested in Nets star: report

NEW YORK — A new team has joined the Kevin Durant sweepstakes, and it’s the same team that pried away another Nets superstar.

Tribune News Service

Report: Kevin Durant sees Boston Celtics as desired landing spot; wants to play with Marcus Smart

Still no indications on Boston's end that such a deal could be in the works -- or even desirable.

USA Today Sports Media Group

Keith Hernandez reveals he hates calling Phillies games, angers the entire city of Philadelphia

Keith Hernandez likes watching good fundamentals.

USA Today Sports Media Group

From analysis to the latest developments in health,
read the most diverse news in one place.

Where Mets’ Edwin Diaz’s amazin’ entrance music ranks on the top all-time best MLB closer entrance songs

Is there anything better than Mr. Met playing the trumpet?

USA Today Sports Media Group

Report: Mekhi Becton’s season could be over

A new report from SNY says the knee injury for Mekhi Becton may be a season-ending one.

USA Today Sports Media Group

The Most Electric Thing in Sports Right Now is Mets Closer Edwin Diaz Entering a Game

Video of his cinematic entrance to the pitching mound goes viral.

Sports Illustrated

Donovan Mitchell talks between Jazz and Knicks to last weeks?

Tommy Beer: Shams Charania, when asked about trade talks between Utah and New York for Donovan Mitchell on the NBA TV broadcast, says he "expects this to be a dance that plays out over the next two-to-three weeks or the rest of the offseason." ...

USA Today Sports Media Group

Read news from The Economist, FT, and more,
with one subscription

Report: Carmelo Return to Knicks Has Been ‘On the Table’

Per the report, New York has discussed the option going back to last year.

Sports Illustrated

Andre Drummond joining Bulls

Shams Charania: Free agent center Andre Drummond is finalizing a deal with the Chicago Bulls, sources tell @TheAthletic @Stadium. Source: Twitter @ShamsCharania What's the buzz on Twitter? The Vertical @ YahooSportsNBA Andre Drummond is finalizing a ...

USA Today Sports Media Group

Isaiah Hartenstein to Knicks

Kelly Iko: Free agent center Isaiah Hartenstein is signing a two-year, $16.7 million deal with the New York Knicks, sources tell @TheAthletic. Source: Twitter @KellyIkoNBA What's the buzz on Twitter? Fred Katz @ FredKatz Very interested to see how ...

USA Today Sports Media Group

Jazz trade Royce O’Neale to Nets

Shams Charania: Utah is trading Royce O'Neale to Brooklyn for a first-round pick, sources tell @TheAthletic @Stadium . Source: Twitter @ShamsCharania What's the buzz on Twitter? Keith Smith @ KeithSmithNBA Poor Royce O'Neale. He's a good player yet ...

USA Today Sports Media Group

Why Sanofi Shares Are Falling Today

The FDA has placed Sanofi SA's (NASDAQ:SNY) Phase 3 studies of tolebrutinib in multiple sclerosis and myasthenia gravis on partial clinical hold. New enrollment in the U.S. is paused, and participants in the U.S. who have been in the trial for fewer than 60 days shall suspend the study drug. The participants who…

Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

Benzinga

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

USA Today Sports Media Group

Knicks’ hiring of Rick Brunson not tied to free-agent pursuit of Jalen Brunson?

One source said Thibodeau wanted him on the Knicks staff from the get-go, but there was concern from some in upper management about his controversial departure from Minnesota when he was reportedly was accused of harassment. Another league source ...

USA Today Sports Media Group

Knicks to hire Rick Brunson, father of free-agent target Jalen Brunson, as assistant coach

The Knicks are finalizing a contract with Rick Brunson, the father of Jalen Brunson, to become an assistant coach on Tom Thibodeau's staff, SNY has learned . Brunson, a nine-year NBA veteran, has been an assistant coach under Thibodeau in Chicago ...

StockNews.com

5 Large-Cap Stocks to Buy Amid the Nasdaq’s Bear Market

The stock market indices are regaining their lost ground, somewhat. However, the tech-heavy Nasdaq Composite remains in a bear market. Hence, we think the large-cap stocks of Comcast (CMCSA), Regeneron (REGN), Microsoft (MSFT), PepsiCo (PEP), and Sanofi (SNY) might be solid bets amid the market correction. Read on.

Benzinga

Sanofi To Pay €400K As Compensation For Epilepsy Drug-Related Side Effects

A French court has ordered Sanofi SA (NASDAQ: SNY) to pay more than €400,000 in damages to a French family whose child had autism caused by its epilepsy drug Valproate.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sanofi Says Sarclisa Shows 'Unprecedented Median Progression-Free Survival' In Multiple Myeloma Patients

Sanofi SA (NASDAQ:SNY) shared the latest results from the Phase 3 IKEMA trial evaluating Sarclisa (isatuximab) in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy. Sarclisa combined with carfilzomib and dexamethasone (Kd) demonstrated a median progression-free survival (mPFS) of 35.7 months, compared to 19.2 months in patients treated with Kd alone. …

Benzinga

Sanofi-AstraZeneca Say New Nirsevimab Data Reinforce Efficacy Against RSV

Sanofi SA (NASDAQ: SNY) and AstraZeneca plc (NASDAQ: AZN) have announced results from a prespecified pooled analysis of nirsevimab in respiratory syncytial virus (RSV).

Benzinga

Dupixent, Consumer Healthcare Lifts Sanofi's Q1 Earnings, Backs FY22 Guidance

Sanofi SA (NASDAQ:SNY) posted a net profit of €2 billion for Q1 FY22, up from €1.57 billion a year ago. Sales reached €9.67 billion, up from €8.59 billion in Q1 FY21. Eczema drug, Dupixent, and consumer healthcare drove the growth. Dupixent alone grew by 45.7% to €1.6 billion, driving Sanofi's specialty care…

Sports Illustrated

Mets’ Bassitt Rips MLB Over ‘Different’ Baseballs After More HBP’s

New York’s starting pitcher criticized the league for a lack of consistency in the baseballs from outing to outing.

Sports Illustrated

Yankees Letter Reveals Past Fine for Sign-Stealing Methods

The fine for using the dugout phone to help relay signs was not been previously reported.

Tribune News Service

Infamous ‘Yankee Letter’ finally published

NEW YORK — After years of legal wrangling, the infamous Yankee Letter from Rob Manfred to Brian Cashman is now public, with a few redactions. Much of the text of the letter was published by SNY on Tuesday, after the Yankees lost a court ruling aiming to keep it sealed.…

StockNews.com

5 Non-Cyclical Stocks to Buy Now if You're Worried About a Recession

As surging inflation and energy prices foster recessionary fears, it could be wise to bet on non-cyclical stocks because they tend to outperform the broader market when economic growth slows. Given the inelastic demand for their companies’ products, we think the shares of United Parcel Service (UPS), British American Tobacco…

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.